Abstract: The invention relates to nitrosourea derivatives, a process for their preparation and pharmaceutical compositions containing them.The nitrosourea derivatives of the invention correspond to the following formula (I): ##STR1## in which: R can represent a hydrogen atom or an alkyl group from 1 to 30 carbon atoms, X represents a hydroxy group or an --NR.sub.1 R.sub.2 group, Y represents a hydrogen atom, a hydroxy group or an --NR'.sub.1 R'.sub.2 group, where R.sub.1 and/or R'.sub.1 each represent a hydrogen atom or a ##STR2## group, Hal being a halogen, and R.sub.2 and/or R'.sub.2 can each represent a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms, R' and R" can represent hydrogen or OH, provided that at least X represents ##STR3## with R.sub.1 representing ##STR4## or Y represents ##STR5## with R'.sub.1 representing ##STR6## and provided that either R' represents hydrogen or R" represents hydrogen, and R' and R" cannot be simultaneously hydrogen atoms.
Type:
Grant
Filed:
April 14, 1988
Date of Patent:
February 20, 1990
Assignee:
Sanofi S.A.
Inventors:
Pierre Roger, Patrick Choay, Claude Monneret, Jean-Paul Fournier, Alain Martin
Abstract: The present invention is dealing with new pentasaccharides of the formula I: ##STR1## These pentasaccharides have anti-thrombotic activity and especially they possess potent anti-Xa activity, inactivate thrombin via HC-II, but do not inactivate thrombin via AT-III.The invention also refers to new tetrasaccharides which may be used as intermediates in the synthesis of the above pentasaccharides.
Type:
Grant
Filed:
July 12, 1988
Date of Patent:
June 20, 1989
Assignees:
Akzo N.V., Sanofi S.A.
Inventors:
Constant A. A. van Boeckel, Tom Beetz, Maurice Petitou
Abstract: The present invention relates to new quinolylglycinamide derivatives corresponding to the following general formula: ##STR1## The invention also relates to a process for preparing these compounds and their therapeutic application as a psychotropic agent.
Type:
Grant
Filed:
May 6, 1986
Date of Patent:
November 29, 1988
Assignee:
Sanofi (S.A.)
Inventors:
Jean-Claude Vernieres, Etienne Mendes, Michel Morre, Peter Keane, Jacques Simiand
Abstract: This invention relates to a therapeutic composition comprising, as active ingredient, a combination of a pyridine derivative having an anti-blood-platelet-aggregation activity and of sulfinpyrazone.Said composition has outstanding anti-blood-platelet-aggregating and antithrombotic properties, both components of the active ingredient functioning according to a synergistic effect.
Abstract: The present invention relates to novel derivatives of alpha-(2-oxo 2,4,5,6,7,7a-hexahydro thieno [3,2-c] 5-pyridyl) phenyl acetic acid corresponding to the following general formula: ##STR1## their addition salts with pharmaceutically-acceptable inorganic or organic acids as well as isomers and their mixtures.The invention also relates to their process of preparation and to medicaments containing these compounds which are of therapeutic use as inhibitors of platelet- and thrombotic-aggregation.
Type:
Grant
Filed:
January 31, 1986
Date of Patent:
April 26, 1988
Assignee:
Sanofi (S.A.)
Inventors:
Alain Badorc, Daniel Frehel, Jean-Pierre Maffrand, Eric Vallee
Abstract: The present invention relates to novel xylan sulfates of average molecular weight comprised between 2000 and 5000 Daltons.The invention also relates to their process of preparation by fractionation and their use in therapeutics as orally active antithrombotic and hypolipaemic agents.
Type:
Grant
Filed:
October 31, 1985
Date of Patent:
December 15, 1987
Assignee:
Sanofi S.A.
Inventors:
Alain Bayol, Francis Blanc, Jacqueline Lansen, Jean-Pierre Maffrand, Jean-Marie Pereillo
Abstract: This invention relates to new xylane sulfates having an apparent molar weight comprised between 7000 and 12000.This invention relates also to a process for their preparation by fractionation, and to the therapeutic application thereof as anti-thrombosis and hypolipemic agents.
Type:
Grant
Filed:
March 23, 1984
Date of Patent:
October 13, 1987
Assignee:
Sanofi S.A.
Inventors:
Alain Bayol, Jacqueline Lansen, Jean P. Maffrand, Jean-Marie Pereillo, Eric Vallee
Abstract: This invention relates to triazolo-pyrimidine derivatives corresponding to the following formula: ##STR1## wherein X represents a 2-pyridyl, 3-pyridyl or 4-pyridyl nucleus optionally substituted by at least one straight-chained or branched C.sub.1-4 alkoxy or alkyl or a hydroxy or cyano group,R.sub.1 represents hydrogen or a straight-chained or branched saturated or unsaturated C.sub.1-5 aliphatic group, andR.sub.2 represents a straight-chained or branched C.sub.1-4 alkyl group, and the pharmaceutically acceptable acid addition salts thereof with inorganic or organic acids.These compounds may be used in therapy, particularly on account of their cardiotonic activity.
Type:
Grant
Filed:
July 9, 1984
Date of Patent:
April 8, 1986
Assignee:
Sanofi, S.A.
Inventors:
Geard Barthelemy, Jean N. Vallat, Andre Hallot
Abstract: The present invention relates to new derivatives of formula: ##STR1## in which: R.sub.3 denotes a halogen, preferably chlorine, or a nitro group,R.sub.4 represents hydrogen or a lower alkyl group having from 1 to 4 atoms of carbon,R.sub.5 represents an atom of halogen, preferably chlorine or fluorine.It also relates to a process for preparing products of formula (II) and to the drugs containing at least one product of formula (II).
Type:
Grant
Filed:
February 3, 1983
Date of Patent:
September 10, 1985
Assignee:
Sanofi S.A.
Inventors:
Kathleen Biziere, Andre Hallot, Jean-Paul Kan
Abstract: This invention relates to a therapeutic composition comprising, as active ingredient, a combination of a pyridine derivative having an anti-blood-platelet-aggregation activity and of sulfinpyrazone.Said composition has outstanding anti-blood-platelet-aggregating and antithrombotic properties, both components of the active ingredient functioning according to a synergistic effect.
Abstract: This invention relates to new thieno [3,2-c] pyridine derivatives having the formula: ##STR1## in which: Y represents the OH group or an OR group in which R is a straight or branched lower alkyl radical, or Y represents a group ##STR2## in which R.sub.1 and R.sub.2 are each independently of each other, hydrogen or a straight or branched lower alkyl group; or R.sub.1 and R.sub.2 form together and with the nitrogen atom to which they are attached a heterocycle which may include a second heteroatom such as oxygen or nitrogen, wherein the latter may be substituted by a lower alkyl or benzyl radical which may be substituted; and X represents hydrogen, a halogen or a lower alkyl radical; and their addition salts with pharmaceutically acceptable mineral or organic acids if Y represents the group OR or ##STR3## or with mineral bases if Y represents OH, as well as the two enantiomers or their mixture.
Type:
Grant
Filed:
July 5, 1983
Date of Patent:
July 16, 1985
Assignee:
Sanofi, S.A.
Inventors:
Daniel Aubert, Claude Ferrand, Jean-Pierre Maffrand
Abstract: 2-Acyl-1,3,4,6,7,11b-hexahydro-2H-pyrazino-[2,1-a]-4-isoquinoleinones having anthelmintic activity of the formula ##STR1## are prepared from 4-acyl-2,6-dioxopierazines by reaction with a phenethyl halide, selective reduction of one of the oxo groups and cyclization, by the novel intermediates of formula ##STR2## in which Y represents O or H, OH.
Abstract: The present invention discloses a 4-[3-(1,1-dimethyl-2-3(3-indolyl)ethylamino)-2-hydroxypropoxy]indole of formula ##STR1## and pharmaceutically acceptable acid salts thereof, which are particularly active on the cardiovascular system.
Abstract: This invention relates to a new thieno-pyridinone derivative of the formula: ##STR1## and its pharmaceutically acceptable inorganic or organic acid addition salts.This invention relates also to a process for the preparation of said compound and to its therapeutic application as blood-platelet anti-aggregation agent and anti-thrombosis agent.
Type:
Grant
Filed:
June 15, 1983
Date of Patent:
February 19, 1985
Assignee:
Sanofi, S.A.
Inventors:
Daniel Frehel, Jean-Pierre Maffrand, Eric Vallee
Abstract: The invention concerns novel 5-o-cyanobenzyl-4, 5, 6, 7-tetrahydrothieno-[3,2-c] pyridine acid addition salts having inhibitory action against blood platelet aggregation without anti-inflammatory activity, and the compositions and methods of use therefor.